1. Introduction {#sec1-ijms-21-01296}
===============

Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver disorders worldwide \[[@B1-ijms-21-01296],[@B2-ijms-21-01296]\]. The incidence of NAFLD is rising in many parts of the world, especially in developed countries \[[@B3-ijms-21-01296]\]. In the United States alone, between 30% and 40% of the adult population is affected with NAFLD \[[@B3-ijms-21-01296]\]. Among children and adolescents, NAFLD is currently the primary form of liver disease; it is estimated that nearly 10% of the US population aged between 2 and 19 has NAFLD \[[@B4-ijms-21-01296]\]. NAFLD has been associated with insulin resistance and metabolic syndrome---a cluster of conditions consisting of high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels---that are key determinants of cardiovascular disease and type 2 diabetes mellitus \[[@B1-ijms-21-01296]\]. Abdominal obesity is a common feature of patients with NAFLD; in obese individuals, the prevalence of NAFLD can exceed 95% \[[@B5-ijms-21-01296]\]. As the epidemic of obesity continues to grow worldwide, so does the prevalence of NAFLD \[[@B5-ijms-21-01296]\].

NAFLD is characterized by the accumulation of fat droplets within the liver cells, a condition known as hepatic '*steatosis*' \[[@B6-ijms-21-01296]\]. Retention of lipids within the cells reflects an impairment of the normal process of synthesis and elimination of fat, primarily triglycerides \[[@B6-ijms-21-01296]\]. Buildup of excess lipids within the cells manifests as the accumulation of vesicles that can displace the nucleus, disrupt cell constituents and, in severe cases, lead to cell rupture/burst \[[@B7-ijms-21-01296]\]. Non-diagnosed and untreated NAFLD can progress from benign steatosis and fatty liver to more permanent and severe liver injury, including non-alcoholic steatohepatitis (NASH) with inflammation and variable fibrosis, cirrhosis, and eventually hepatocellular carcinoma \[[@B8-ijms-21-01296]\].

Although distinct risk factors for NAFLD have been identified, the exact cause(s) of this disease and the underlying mechanisms of its initiation and progression remain unknown. Accumulating evidence shows that exposure to environmental toxicants, including secondhand smoke (SHS), contributes to the development of NAFLD by promoting mitochondrial dysfunction and oxidative stress within the hepatocytes \[[@B9-ijms-21-01296],[@B10-ijms-21-01296],[@B11-ijms-21-01296],[@B12-ijms-21-01296]\]. Several studies have shown that cigarette smoking is an independent risk factor for the onset of NAFLD \[[@B13-ijms-21-01296],[@B14-ijms-21-01296],[@B15-ijms-21-01296],[@B16-ijms-21-01296]\], and significantly associated with increased intrahepatic fat \[[@B17-ijms-21-01296]\] and advanced liver fibrosis \[[@B18-ijms-21-01296],[@B19-ijms-21-01296]\]. Survey based reports have also shown an association between exposure to SHS and development of NAFLD in children \[[@B20-ijms-21-01296],[@B21-ijms-21-01296]\] and in never-smoking women \[[@B22-ijms-21-01296]\]. A more recent systematic review and meta-analysis established that SHS increases the risk of NAFLD approximately 1.38 times \[[@B23-ijms-21-01296]\]. Animal studies have also provided support for a potential role of SHS in the genesis and progression of NAFLD \[[@B24-ijms-21-01296],[@B25-ijms-21-01296],[@B26-ijms-21-01296]\]. Yuan et al. \[[@B26-ijms-21-01296]\] have shown that subchronic exposure of mice to SHS stimulates hepatic fatty acids synthesis by modulating two key regulators of lipid metabolism, including AMP-activated protein kinase (AMPK) and sterol regulatory element binding protein-1c (SREBP-1c). The SHS-exposed mice in the Yuan et al. study developed hepatic steatosis, which---as the authors inferred---would lead to NAFLD development \[[@B26-ijms-21-01296]\]. De la Monte et al. \[[@B25-ijms-21-01296]\] have demonstrated that A/J mice exposed to SHS exhibit progressive liver injury and steatohepatitis, with impairments in hepatic insulin and insulin-like growth factor (IGF) signaling. Azzalini et al. \[[@B24-ijms-21-01296]\] have shown that nose-only exposure of Zucker '*obese*' rats to cigarette smoke, mimicking SHS exposure, worsens the histological severity of NAFLD, increases the burden of oxidative stress, and induces hepatocellular apoptosis \[[@B24-ijms-21-01296],[@B27-ijms-21-01296]\].

Although informative, most animal studies investigating the role of SHS exposure in the development of NAFLD have been conducted in rodents fed with high-fat diets that contain cholate, a known cause of liver inflammation and dysfunction \[[@B28-ijms-21-01296]\]. As a result, the role of SHS exposure, independently of diet, in the genesis of NAFLD is not delineated. In addition, the above studies are limited in scope, as they have focused on the analysis of '*select*' target genes. Therefore, a comprehensive study interrogating the whole transcriptome is needed to establish the global effects of SHS on the regulation of genes that govern NAFLD development. Towards this end, we have constructed the whole hepatic transcriptome in relation to liver histology in 'standard diet-fed' mice subchronically exposed to SHS according to our published protocol \[[@B29-ijms-21-01296],[@B30-ijms-21-01296],[@B31-ijms-21-01296],[@B32-ijms-21-01296]\]. More specifically, we have investigated the relationship between global regulation of genes and molecular pathways and gene networks and histological changes indicative of liver injury and hepatic steatosis (i.e., lipid accumulation, inflammation, fibrosis, and glycogen deposition) in the SHS-exposed mice both upon cessation of exposure and after one-month recovery in clean air.

2. Results {#sec2-ijms-21-01296}
==========

2.1. Genome-Wide Gene Expression Changes in the Liver of Secondhand Smoke (SHS)-Exposed Mice {#sec2dot1-ijms-21-01296}
--------------------------------------------------------------------------------------------

As shown in [Figure 1](#ijms-21-01296-f001){ref-type="fig"}A, subchronic exposure of mice to SHS elicited a significant transcriptomic response, as reflected by the large number of aberrantly expressed transcripts in the SHS-exposed *versus* control mice. More specifically, there were 473 aberrant transcripts in the SHS-exposed mice relative to age-matched controls ([Figure 1](#ijms-21-01296-f001){ref-type="fig"}A; [Table S1](#app1-ijms-21-01296){ref-type="app"}). One-month recovery in clean air resulted in slight attenuation of the transcriptional changes in the SHS-exposed mice, although the number of aberrantly expressed transcripts remained considerably high in the exposed mice undergone recovery (i.e., 222 transcripts). There were 210 overlapping aberrant transcripts in the SHS-exposed mice pre- and post-recovery.

Principal component analysis (PCA) and hierarchical clustering analysis in Partek GS^®^ showed clustering of the datasets from mice belonging to the same experimental or control groups, which confirms a uniform gene expression pattern within each experimental/control group ([Figure 1](#ijms-21-01296-f001){ref-type="fig"}B,C). Compiled lists of differentially expressed transcripts in experimental groups relative to controls are shown in [Table S1](#app1-ijms-21-01296){ref-type="app"}. The lists identify both common and unique deregulated genes in the SHS-exposed mice before and after one-month recovery. Overall, there was a high degree of overlap between differentially expressed genes in the SHS-exposed mice before and after recovery in clean air ([Figure 1](#ijms-21-01296-f001){ref-type="fig"}A; [Table S1](#app1-ijms-21-01296){ref-type="app"}).

2.2. Modulation of Functional Networks and Biological Pathways in SHS-Exposed Mice {#sec2dot2-ijms-21-01296}
----------------------------------------------------------------------------------

To investigate the lasting effects of SHS, we selected the dataset generated by comparing both the SHS^4m^ and SHS^4m+1m\ recovery^ groups vs. controls (Set 3; [Figure 1](#ijms-21-01296-f001){ref-type="fig"}A). Of the 210 common transcripts, 201 mapped to known IDs, for a total of 153 unique genes ([Table 1](#ijms-21-01296-t001){ref-type="table"}). Of the 153 differentially expressed genes (DEGs), 63 (\>41%) are known to participate in lipid homeostasis, specifically uptake, synthesis, and accumulation of lipids, as well as fatty acids oxidation and secretion ([Table 1](#ijms-21-01296-t001){ref-type="table"}). Eighteen of these 63 genes (\>28%) are specifically involved in liver steatosis ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}A). To characterize the gene networks and functional pathways associated with the 153 unique genes, we performed gene ontology and functional network analyses, using a combination of Database for Annotation, Visualization and Integrated Discovery (DAVID) and Ingenuity*^®^* Pathway Analysis (IPA^®^). Applying the DAVID annotation clustering analysis tool, we discovered twenty-eight relevant biological clusters. The top functional category with the highest enrichment score consisted of gene sets involved in lipid metabolism ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}B). Based on DAVID analysis, we also detected deregulated genes that are involved in oxidoreductase reactions ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}B). The latter is consistent with SHS being a well-known inducer of reactive oxygen species (ROS) and oxidative stress \[[@B33-ijms-21-01296],[@B34-ijms-21-01296]\]. Other highly enriched categories included genes implicated in endoplasmic reticulum function, circadian regulation of gene expression, lipid biosynthesis, and transcription regulation ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}B).

IPA^®^ analysis of the 153 unique DEGs showed disruption of similar gene networks and functional pathways in the SHS-exposed mice, both pre- and post-recovery. As shown in [Figure S1](#app1-ijms-21-01296){ref-type="app"}, the top impacted networks comprised of genes involved in lipid metabolism and biosynthesis. Other affected gene networks included molecules implicated in behavior and nervous system development and function, cell death and survival, drug metabolism and small molecule biochemistry ([Figure S1](#app1-ijms-21-01296){ref-type="app"}). The top canonical pathways impacted in the SHS-exposed mice, both pre- and post-recovery, included the lipopolysaccharide (LPS)/IL-1 mediated inhibition of the Retinoid X Receptor (RXR) function (*p* = 3.11 × 10^−6^), the adipogenesis pathway (*p* = 3.97 × 10^−6^), and the nicotine degradation II pathway (*p* = 4.98 × 10^−6^) ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}C). Members of these pathways are known to participate in the negative acute phase response (APR), which down-regulates hepatic genes with crucial physiological roles, in response to liver injury, infection, and/or inflammation. Reduction of key molecules within these pathways ultimately leads to impaired metabolism, transport and/or biosynthesis of lipid, cholesterol, bile acid, and xenobiotics \[[@B35-ijms-21-01296]\].

Next, we used the IPA^®^ Upstream Regulator Analysis tool to identify the upstream regulators that are likely to account for the aberrant expression of the 63 lipid-specific genes. Based on IPA^®^ prediction analysis, we identified the Conserved Helix-Loop-Helix Ubiquitous Kinase (CHUK) as the top master regulator with an activation *z*-score of 2.376. CHUK is a member of the serine/threonine protein kinase family, and plays an essential role in the NF-κB signaling pathway. The NF-κB pathway is activated by multiple stimuli, including DNA damage \[[@B36-ijms-21-01296]\] and is involved in inflammation, fibrosis and hepatocarcinogenesis \[[@B37-ijms-21-01296]\]. Our prediction analysis shows that CHUK modulates a complex network of upstream regulators (IKBKG, IKBKB, SP1, STAT1, NFKBIA, FOXO3, NF-κB complex, RELA, NFKB1 and TP53), which may work together to elicit the transcriptional changes observed in a subset of lipid-specific genes (25 out of 63 genes). Thirteen of these 25 target genes are presumably under control of the *TP53* gene ([Figure 3](#ijms-21-01296-f003){ref-type="fig"}). Four of the TP53-regulated genes, i.e., *Rgs16*, *Lpin1*, *Hmox1*, and *Tsc22d3*, are known to be involved in liver steatosis ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}A).

2.3. Initiation and Progression of Liver Steatosis in SHS-Exposed Mice {#sec2dot3-ijms-21-01296}
----------------------------------------------------------------------

To investigate whether in vivo exposure of mice to SHS causes anomalies in the lipogenic pathways and induces hepatic steatosis, we performed Oil Red O (ORO) staining on liver sections from SHS-exposed mice in comparison to controls. As illustrated in [Figure 4](#ijms-21-01296-f004){ref-type="fig"}A (upper panels), there was a significant increase in fat deposition (steatosis) within the liver cells of SHS-exposed mice, immediately after treatment, as compared to age-matched controls (*p* = 0.000334). The extent of liver steatosis in the SHS-exposed mice was significantly enhanced after one-month recovery in clean air (SHS^4m+1m\ recovery^ vs. SHS^4m^; *p* = 0.000017 and SHS^4m+1m\ recovery^ vs. Control 1; *p* = 0.000276). While reaffirming the steatogenic properties of tobacco smoke on hepatocytes \[[@B26-ijms-21-01296],[@B38-ijms-21-01296]\], these findings show that SHS-induced liver steatosis in vivo is likely to progress and become pervasive. To further determine whether the SHS-induced liver steatosis persisted and/or intensified over prolonged periods of time, we measured fat accumulation in the liver of a subgroup of SHS-exposed mice undergone seven-month recovery in clean air (SHS^4m+7m\ recovery^). As shown in [Figure 4](#ijms-21-01296-f004){ref-type="fig"}A (lower panels), extended recovery in clean air resulted in progression of the induced liver steatosis in the SHS-exposed mice (SHS^4m+7m\ recovery^ *vs* SHS^4m^; *p* \< 0.00001). The SHS-exposed mice undergone seven-month recovery also showed significantly higher levels of hepatic fat accumulation than age-matched control mice (SHS^4m+7m\ recovery^ vs. Control 2; *p* = 0.000114).

Ogrodnik et al. \[[@B39-ijms-21-01296]\] have recently shown that cellular senescence drives age-dependent hepatic fat accumulation and steatosis through induction of mitochondrial dysfunction, which, in turn, reduces fat metabolism. Consistent with the findings of that study, we observed higher levels of fat accumulation in the liver of control older mice than younger mice (Control 2 vs. Control 1; *p* = 0.000508). Altogether our data indicate that in vivo exposure of mice to SHS not only initiates liver steatosis but also exacerbates age-dependent progression of hepatic fat deposition.

2.4. Histopathological Evaluation of Liver Injury in SHS-Exposed Mice {#sec2dot4-ijms-21-01296}
---------------------------------------------------------------------

Several deregulated genes detected in our dataset (*ACOT1*, *ADIPOR2*, *ADORA1*, *EGR1*, *HMOX1*, *IL6R*, *LPIN1*, *NROB2*, and *POR*) are known to play a crucial role in liver inflammation ([Table 1](#ijms-21-01296-t001){ref-type="table"}). Three genes in particular, ACOT1, ADIPOR2 and ADORA1, are associated with nonalcoholic steatohepatitis \[[@B40-ijms-21-01296],[@B41-ijms-21-01296]\]. Deregulation of IL6, a potent pleiotropic cytokine, and the hepatic IL6 receptor (IL6R) are important contributors to the immune response and acute inflammation in vivo. To further investigate whether exposure to SHS predisposes mice to other forms of liver injury, including inflammation and/or fibrosis, paraffin-embedded liver sections from experimental and control mice were stained with H&E, Masson's trichrome and Periodic Acid-Schiff (PAS) stain. As shown in [Figure 4](#ijms-21-01296-f004){ref-type="fig"}B and [Figure 5](#ijms-21-01296-f005){ref-type="fig"}, we observed a mild increase in lobular inflammation infiltrates and collagen deposition (blue areas) in the liver of SHS^4m^ and SHS^4m+1m\ recovery^ mice, as compared to control mice. Consistent with previous findings \[[@B25-ijms-21-01296]\], a more pronounced phenotype manifested in the liver of mice post-recovery. Liver sections from SHS^4m+1m\ recovery^ mice showed a disrupted cord-like architecture with foci of necrosis, apoptosis, inflammation and macrovesicular steatosis ([Figure 4](#ijms-21-01296-f004){ref-type="fig"}B, panels c,f). A great variability in the size and nuclear morphology of hepatocytes was also observed in these mice ([Figure 4](#ijms-21-01296-f004){ref-type="fig"}B, panel f). Our data show that exposure to SHS is likely to induce early signs of inflammation and fibrosis, with effects that persist even after termination of exposure. Furthermore, the results obtained by histopathological examination are in good agreement with the gene expression data.

A recent study has shown that lack of liver glycogen causes hepatic insulin resistance and steatosis in mice \[[@B42-ijms-21-01296]\]. To examine whether exposure to SHS affects glycogen metabolism, we also performed PAS staining on liver sections from SHS-exposed mice and controls, before and after recovery. As shown in [Figure 5](#ijms-21-01296-f005){ref-type="fig"}, liver tissues from SHS^4m^ mice displayed prominent loss of glycogen (*h*, *k*), while hepatocytes of SHS^4m+1m\ recovery^ mice and controls showed intense and extensive PAS-positive staining (i, *l*), indicative of glycogen accumulation. The divergent patterns of glycogen loss/buildup in the liver of SHS-exposed vs. control mice are consistent with body weight gains of the corresponding animals ([Figure S2](#app1-ijms-21-01296){ref-type="app"}). Whilst mice in the control group gained body weight steadily throughout the sham-exposure and subsequent recovery, the mice in the experimental group showed a nearly flat pattern of body weight gain during the four-month SHS exposure. The SHS-exposed mice, however, started to re-gain weight immediately after the termination of exposure ([Figure S2](#app1-ijms-21-01296){ref-type="app"}) \[[@B29-ijms-21-01296]\]. In confirmation, we observed up-regulation of glycogen synthase 2 (Gys2) in the SHS^4+1m\ recovery^ mice relative to controls ([Table S1](#app1-ijms-21-01296){ref-type="app"}), indicating that synthesis of glycogen is resumed following recovery in clean air.

2.5. Validation of Genome-Wide Gene Expression Data by Reverse Transcription-Quantitative PCR (RT-qPCR) {#sec2dot5-ijms-21-01296}
-------------------------------------------------------------------------------------------------------

To validate the genome-wide gene expression data, we randomly selected several up-regulated or down-regulated targets from the 153 gene list ([Table 1](#ijms-21-01296-t001){ref-type="table"}), and quantified the expression level of each gene by standard Reverse Transcription Quantitative PCR (RT-qPCR). Mean normalized expression levels of all selected genes in the SHS-exposed mice, before and after recovery, relative to age-matched controls are shown in [Figure 6](#ijms-21-01296-f006){ref-type="fig"}A. Consistent with the microarray data, RT-qPCR analysis of total RNA from the liver of SHS-exposed mice pre-recovery showed a \~13-fold increase in relative expression level of the regulator of G-protein signaling 16 gene (*Rgs16*). The expression level of *Rgs16* continued to increase in the SHS-exposed mice after one-month recovery, reaching \~46 times higher than that in age-matched controls ([Figure 6](#ijms-21-01296-f006){ref-type="fig"}A). The regulator of G-protein signaling 16 gene (*Rgs16*) is a key determinant of lipid metabolism and biosynthesis \[[@B43-ijms-21-01296]\]. RGS16 has been shown to induce hepatic steatosis by inhibiting G~i~/G~q~-mediated fatty acid oxidation. Transgenic mice specifically expressing RGS16 protein in their hepatocytes have shown to have elevated levels of triglycerides and accumulation of fat deposits in their liver compared to control littermates, while *Rgs16* knockout mice have displayed the opposite phenotype \[[@B43-ijms-21-01296]\].

Likewise, over-expression of the *Lipin1* (*Lpin1*) gene, which plays a crucial role in liver metabolism \[[@B44-ijms-21-01296],[@B45-ijms-21-01296]\], was confirmed in the SHS-exposed mice by RT-qPCR analysis. LPIN1 is a bi-functional protein with distinct roles in lipid metabolism, depending on its subcellular localization \[[@B46-ijms-21-01296]\]. In the nucleus, *Lpin1* interacts with the peroxisome proliferator-activated receptor α (PPARα) and PPARγ coactivator 1α (PGC-1α) to modulate the expression of genes involved in mitochondrial fatty acid oxidation \[[@B44-ijms-21-01296]\]. In the cytoplasm, LPIN1 functions as a Mg^2+^-dependent phosphatidate phosphatase enzyme that catalyzes the conversion of phosphatidate to diacylglycerol, a key step in the biosynthesis of triacylglycerol \[[@B45-ijms-21-01296]\]. As shown in [Figure 6](#ijms-21-01296-f006){ref-type="fig"}A, the expression level of *Lpin1* was increased in the SHS-exposed mice pre-recovery (2.5-fold) and continued to rise after one month of recovery (\~5-fold) relative to age-matched controls. Of significance, both *Rgs16* and *Lpin1* were identified by IPA^®^ analysis as part of a subset of molecules affecting liver steatosis in the SHS-exposed mice ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}A).

We also confirmed over-expression of the metallothionein 1 (*Mt1*) gene in the SHS-exposed mice before and after one-month recovery ([Figure 6](#ijms-21-01296-f006){ref-type="fig"}A). *Mt1* and its isoform *Mt2* belong to a family of small cysteine-rich and heavy metal binding proteins, the metallothioneins (MTs), that are involved in protective stress responses \[[@B47-ijms-21-01296]\]. Synthesis of MTs has been reported to significantly increase due to a variety of stimuli, including oxidative stress, cytotoxicity, irradiation, and DNA damage \[[@B47-ijms-21-01296]\]. Furthermore, we detected SHS-induced up-regulation of the ubiquitin specific peptidase 2 (*Usp2*) gene and its downstream target, the period circadian clock 1 (*Per1*) gene, in the SHS-exposed mice vs. controls. The transcription levels of these two genes were significantly elevated in the SHS-exposed mice, both before and after one-month recovery, as compared to age-matched controls ([Figure 6](#ijms-21-01296-f006){ref-type="fig"}A).

Moreover, we verified the SHS-induced down-regulation of other functionally important genes. The hepatocyte nuclear factor 6 (*Hnf6/Onecut1*) is a member of the *one cut* family of transcription factors, which modulates expression of numerous genes required for hepatocyte function. *Hfn6* is known to be down-regulated during liver injury \[[@B48-ijms-21-01296]\]. The elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 (*Elovl3*) gene encodes a protein that plays a key role in elongation of long chain fatty acids, thus providing precursors for synthesis of sphingolipids and ceramides \[[@B49-ijms-21-01296]\]. Down-regulation of *Onecut1* and *Elovl3* transcripts was confirmed in the SHS-exposed mice upon termination of exposure (0.20-fold and 0.17-fold, respectively) and remained persistent in the counterpart mice undergone one-month recovery in clean air (0.78-fold and 0.22-fold, respectively) ([Figure 6](#ijms-21-01296-f006){ref-type="fig"}A).

3. Discussion {#sec3-ijms-21-01296}
=============

First, we analyzed the hepatic transcriptome of SHS-exposed mice, pre- and post-recovery, using genome-wide gene expression analysis followed by functional network and molecular pathway analyses. As shown in [Figure 1](#ijms-21-01296-f001){ref-type="fig"}A and [Table S1](#app1-ijms-21-01296){ref-type="app"}, SHS-exposure resulted in a significant transcriptomic response, with several hundred differentially expressed transcripts being detectable in the exposed mice immediately after treatment. One-month recovery in clean air only partially mitigated the SHS-induced transcriptional changes as the number of aberrant transcripts in the exposed mice undergone recovery remained substantially high ([Figure 1](#ijms-21-01296-f001){ref-type="fig"}A and [Table S1](#app1-ijms-21-01296){ref-type="app"}). The persistent transcriptional changes in the SHS-exposed mice predominantly affected genes and functional networks involved in lipid metabolism and biosynthesis as well as in regulation of the endoplasmic reticulum where manufacturing of lipids occurs ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}B, [Figure S1](#app1-ijms-21-01296){ref-type="app"} and [Table 1](#ijms-21-01296-t001){ref-type="table"}). Of the common DEGs in the SHS-exposed mice pre- and post-recovery, 41% are known to modulate lipid metabolism, with 28% being specifically involved in the development of hepatic steatosis ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}A and [Table 1](#ijms-21-01296-t001){ref-type="table"}).

Upstream Regulator Analysis by IPA^®^ identified a complex network of eleven transcription factors and/or regulators (CHUK, IKBKG, IKBKB, SP1, STAT1, NFKBIA, FOXO3, NF-κB complex, RELA, NFKB1 and TP53) that are likely to account for the observed deregulation of lipid metabolism-specific genes and associated pathways in the SHS-exposed mice ([Figure 3](#ijms-21-01296-f003){ref-type="fig"}). This network includes NF-κB, whose activation in non-parenchymal cells is generally recognized to promote inflammation, fibrosis and hepatocarcinogenesis \[[@B37-ijms-21-01296]\]. Of significance is also the predicted activation of TP53, a preferential target of DNA-damaging agents, such as tobacco smoke carcinogens \[[@B30-ijms-21-01296],[@B50-ijms-21-01296],[@B51-ijms-21-01296]\], and a key regulator in fatty liver and insulin resistance \[[@B52-ijms-21-01296]\]. TP53 interacts with the NK-kB complex, and crosstalk between the TP53 and NF-kB transcription factors has been shown to play a pivotal role in determining the cellular response to certain stimuli, e.g., DNA damage \[[@B53-ijms-21-01296]\]. The predicted activation of TP53 is in accordance with the expression status of several downstream lipid targets found in the SHS-exposed mice, both before and after recovery in clean air ([Figure 3](#ijms-21-01296-f003){ref-type="fig"}).

A novel finding of our study is the SHS-induced up-regulation of *Rgs16* and *Lpin1*, two TP53 downstream effectors with crucial roles in lipid metabolism and liver steatosis ([Figure 2](#ijms-21-01296-f002){ref-type="fig"}A). RGS16 is known to be induced by doxorubicin in cells expressing wild-type p53 \[[@B54-ijms-21-01296]\]. In normal lung fibroblasts, RGS16 is transcriptionally activated by exogenous expression of p53, either individually or in combination with retinoblastoma 1 \[[@B55-ijms-21-01296]\]. TP53 can also up-regulate the expression of *Lpin1* via three p53 binding sites located on the first intron of the gene \[[@B56-ijms-21-01296]\]. Whole body γ-irradiation of wild-type p53 mice, but not p53^−/−^ mice, has been shown to cause up-regulation of *Lpin 1* in several organs, with a pattern of expression resembling that of typical p53-responsive genes, including the *p21^WAF1^* gene \[[@B56-ijms-21-01296]\]. In addition to being *bona fide* targets of p53, *Rgs16* and *Lpn1* contain potential sterol regulatory element (SRE) binding sites for SREBP-1, a key regulator of lipid metabolism under the negative control of AMPK \[[@B57-ijms-21-01296]\].

A growing number of studies has shown a 'noncanonical' role for p53 in modulating lipid metabolism by either transcriptional regulation of target molecules involved in fatty acid synthesis and oxidation and lipid droplet formation or via direct protein-protein interactions \[[@B58-ijms-21-01296],[@B59-ijms-21-01296],[@B60-ijms-21-01296],[@B61-ijms-21-01296]\]. Based on our results, we propose a model in which SHS induces TP53 via the DNA-damage response pathway, the ataxia--telangiectasia mutated/ataxia--telangiectasia and Rad3 related (ATM/ATR) kinase pathway). Active TP53, in turn, transcriptionally activates *Rgs16* and *Lpin1*, and most likely additional steatogenic genes in a tissue-specific context, ultimately leading to liver steatosis ([Figure 6](#ijms-21-01296-f006){ref-type="fig"}B). Alternatively, SHS can cause mutations in the *TP53* gene, and gain-of-function mutant forms of TP53 have been found to enhance fatty acid synthesis by inhibitory interaction with AMPKα, and consequent activation of SREBP-1 ([Figure 6](#ijms-21-01296-f006){ref-type="fig"}B) \[[@B60-ijms-21-01296]\]. In turn, SREBP-1 can transcriptionally activate *Rgs16* and *Lpin1* through the SRE binding sites located on these genes. Yuan et al. have previously reported inactivation of AMPK and activation of SREBP-1c concurrent with hepatic lipid accumulation in mice fed with high-fat-diet and exposed to SHS \[[@B26-ijms-21-01296]\]. Altogether, the deregulation of *Rgs16* and *Lpin1* in the SHS-exposed mice found in our study may provide novel insights into the interplay of carcinogen exposure, TP53-dependent response, and metabolic liver disease. Work in our laboratory is currently underway to further investigate the herein proposed model of SHS-induced hepatic steatosis via the TP53 pathway.

Lastly, the perturbation of key lipid genes in the SHS-exposed mice, which persisted after recovery in clean air, is highly consistent with the progressive accumulation of fat and other adverse histological changes observed in the liver of corresponding animals ([Figure 4](#ijms-21-01296-f004){ref-type="fig"} and [Figure 5](#ijms-21-01296-f005){ref-type="fig"}). As shown in [Figure 4](#ijms-21-01296-f004){ref-type="fig"}A, the extent of fat accumulation in the liver of SHS-exposed mice progressively increased after recovery time in clean air ([Figure 4](#ijms-21-01296-f004){ref-type="fig"}A). Furthermore, SHS-exposed mice undergone recovery displayed more pronounced signs of liver injury, including disorganized lobular architecture, foci of inflammation, necrosis, and variable fibrosis ([Figure 4](#ijms-21-01296-f004){ref-type="fig"}B and [Figure 5](#ijms-21-01296-f005){ref-type="fig"}). One possible explanation for this observation is that the cascade of events triggered by exposure to SHS can further progress, even in the absence of SHS, and cause potentially irreversible liver injury. According to the 'multiple-hit' hypothesis, multiple events are required to promote NAFLD initiation and progression. Based on our results, SHS-induced disruption of lipid homeostasis with consequent steatosis may constitute the first hit. Additional factors (metabolic, environmental, genetic and/or epigenetic mechanisms) can further exacerbate liver injury mostly through modulation of pathways involved in mitochondrial dysfunction, oxidative stress, fatty acid biosynthesis, and inflammation, thus, leading to more severe forms of NAFLD. In other words, the first hit (SHS-induced liver steatosis) can increase the susceptibility to subsequent hits, and this could explain why we observed more pronounced effects in SHS^4m+1m\ recovery^ mice. Future follow up studies are needed to investigate the likelihood of the above scenarios in human populations.

4. Materials and Methods {#sec4-ijms-21-01296}
========================

4.1. Animal Care and Maintenance {#sec4dot1-ijms-21-01296}
--------------------------------

This study was conducted in accordance with the recommendations described in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and all efforts were made to minimize animal suffering \[[@B62-ijms-21-01296]\]. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the City of Hope (Protocol Number: 09012, 07 January 2009). All mice were fed a standard diet consisting, at a caloric level, of 25% proteins, 13% fat, and 62% carbohydrates (PicoLab^®^ Rodent Diet 20, PMI Nutrition International, LLC., Brentwood, MO, USA). At all times, including the exposure phase and recovery period, the mice had access to food and water ad libitum.

4.2. Smoking Machine and SHS Exposure {#sec4dot2-ijms-21-01296}
-------------------------------------

The smoking machine and exposure protocol have been described in detail in \[[@B29-ijms-21-01296],[@B30-ijms-21-01296]\]. Briefly, SHS was generated using a custom-made TE-10 smoking machine (Teague Enterprises, Woodland, CA, USA). The TE-10 smoking machine is a microprocessor-controlled unit that can generate mainstream smoke, sidestream smoke, or a combination of the two. The machine was programmed to burn 3R4F Reference Kentucky cigarettes (Tobacco Research Institute, University of Kentucky, Lexington, KY, USA), and produce a mixture of sidestream smoke (89%) and mainstream smoke (11%). This formulation is conventionally used to mimic SHS for in vivo exposure and is representative of the SHS inhaled by humans in real life \[[@B32-ijms-21-01296],[@B63-ijms-21-01296],[@B64-ijms-21-01296]\].

At the outset, all experimental mice underwent an acclimatization period during which they were gradually exposed 'whole body' to incremental doses of SHS. Following the acclimatization period, the mice were maintained on a SHS exposure regimen, which included 5 h per day, 5 days per week, and four-month whole body exposure to SHS, produced by continuous burning of 7--9 cigarettes. The average concentrations of total suspended particulate (TSP) in the exposure chambers were 233.0 ±15.4 mg/m^3^ at any given time during the four-month SHS exposure. The respective average TSP concentrations correspond to SHS generated through continuous smoking of 8.0 ± 0.5 cigarettes, at any given time during the four-month SHS exposure \[[@B29-ijms-21-01296]\].

We note that whole body smoke exposure in rodents may result in residual transdermal and gastrointestinal absorption of smoke particles consequent to grooming \[[@B30-ijms-21-01296]\]. However, 'nose-only' exposure can cause stress and discomfort for the animals, which would be pronounced in long-term studies, such as the present one. Therefore, we chose whole body exposure of mice to SHS based on tolerability and practicality of this approach and its compatibility with our study design. In addition, whole body smoke exposure in mice recapitulates real-life human exposure to SHS \[[@B30-ijms-21-01296]\].

4.3. Study Design {#sec4dot3-ijms-21-01296}
-----------------

Adult male mice (6--8 weeks old), on a C57BL/6 genetic background, were randomly assigned to two groups, including (1) 'experimental' (SHS exposure) and (2) 'control' (sham-treatment in clean air). The experimental group was divided in two subgroups (5 mice per subgroup), including four-month SHS exposure (SHS^4m^) and four-month SHS exposure plus one-month recovery in clean air (SHS^4m+1m\ recovery^). Age-matched control mice were similarly subdivided in sham-treatment subgroups, with and without recovery (5 mice per subgroup). The sham-treated mice were exposed to filtered high-efficiency particulate air (HEPA) in lieu of SHS, as described previously \[[@B29-ijms-21-01296],[@B30-ijms-21-01296],[@B31-ijms-21-01296],[@B32-ijms-21-01296]\]. At the end of all experiments, the SHS-exposed and control mice were euthanized by CO~2~ asphyxiation and various tissues and organs, including the liver, were harvested and kept at −80 °C until further analysis. We note that based on life span, four-month SHS exposure in mice is equivalent to approximately 12 years human exposure to SHS, which is a realistic and biologically relevant exposure scenario in real-life. In our previously published studies \[[@B29-ijms-21-01296],[@B30-ijms-21-01296],[@B31-ijms-21-01296],[@B32-ijms-21-01296],[@B65-ijms-21-01296],[@B66-ijms-21-01296]\], we have also verified that four-month SHS exposure is sufficient to elicit significant genotoxic, epigenetic, and transcriptomic responses in various organs and tissues of male C57BL/6 mice. We have also confirmed that five mice per group are sufficient to yield, at a minimum, a study power of 1 − β = 80%, and statistically significant results at *p* \< 0.05.

4.4. Genome-Wide Gene Expression Analysis {#sec4dot4-ijms-21-01296}
-----------------------------------------

To construct the hepatic transcriptome in SHS-exposed mice, we used the GeneChip*^®^* Mouse Genome 430 2.0 Array (originally from Affymetrix Inc., Santa Clara, CA, USA; currently Thermo Fisher Scientific, Waltham, MA, USA). This microarray platform enables interrogation of over 39,000 transcripts and variants from more than 34,000 well-characterized mouse genes. Briefly, total RNA was isolated from liver tissues of SHS-exposed mice and controls, using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Synthesis of double-stranded cDNA from total RNA, fragmentation, hybridization, staining, and microarray scanning were performed according to the manufacturer's instructions (Affymetrix Inc.). Quality control evaluation and processing and analysis of expression data were performed using the Affymetrix Expression Console™ software (Affymetrix Inc.). The Bioconductor package 'ArrayTools' was used to identify differentially expressed genes in experimental groups relative to controls, as described previously \[[@B67-ijms-21-01296]\]. To establish gene expression trends within each experimental group, significant gene lists were examined by hierarchical clustering analysis and principal component analysis (PCA) using the Partek*^®^* Genomics Suite*^®^* software (Partek Incorporated, St. Louis, MO, USA). Raw microarray data have been deposited in the Gene Expression Omnibus database at NCBI (accession number: GSE139440; htttp://[www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)).

4.5. Gene Ontology and Canonical Pathways Analysis {#sec4dot5-ijms-21-01296}
--------------------------------------------------

Gene ontology (GO) analysis was performed using a combination of the Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Tool v.6.8 \[[@B68-ijms-21-01296]\] and the Ingenuity*^®^* Pathway Analysis (IPA*^®^*) v.9 tool (QIAGEN Bioinformatics, Redwood City, CA, USA; [www.qiagenbioinformatics.com](www.qiagenbioinformatics.com)). The Functional Clustering Analysis tool in DAVID was used to group together similar annotation terms for all categories, while functional identification of gene networks, canonical pathways, and upstream regulators was done by IPA*^®^*.

4.6. Histological Examination {#sec4dot6-ijms-21-01296}
-----------------------------

For histological visualization of fat content and neutral triglycerides, we performed Oil Red O (ORO) staining on liver sections prepared from SHS-exposed mice and controls, according to a published protocol \[[@B69-ijms-21-01296]\]. Bright-field images were captured with an Olympus microscope (Camera Model DP27, Tokyo, Japan), at several magnifications, using the CellSens Standard software (Olympus, Tokyo, Japan). Quantification of lipid droplets in the ORO-stained slides was achieved by measuring the area occupied by red pixels, in ImageJ software (<https://imagej.nih.gov/ij/>), as described previously \[[@B69-ijms-21-01296]\].

Paraffin-embedded liver sections were stained with hematoxylin and eosin (H&E), Masson's trichrome and Periodic Acid-Schiff (PAS) stain according to standard procedures \[[@B70-ijms-21-01296],[@B71-ijms-21-01296]\]. Images were acquired with the Philips IntelliSite Pathology Solutions (PIPS) system.

4.7. Reverse Transcription Quantitative PCR (RT-qPCR) {#sec4dot7-ijms-21-01296}
-----------------------------------------------------

For validation purposes, we used a standard RT-qPCR protocol \[[@B66-ijms-21-01296]\] to determine the expression level of single up-regulated or down-regulated genes identified by microarray analysis. Detailed descriptions for RT-qPCR method are available in [Supplementary Material](#app1-ijms-21-01296){ref-type="app"}.

5. Conclusions {#sec5-ijms-21-01296}
==============

We have demonstrated, for the first time, that subchronic exposure of mice to SHS, independently of diet, induces liver steatosis by modulating genes and functional pathways involved in lipid metabolism. Our findings underscore how an environmental carcinogen, such as SHS, in addition to cancer-causing effects, may contribute to other adverse health consequences, specifically metabolic liver disease.
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![Global gene expression profiling in secondhand smoke (SHS)-exposed mice. (**A**) Differentially expressed transcripts identified in various contrast groups as compared to controls. (**B**) Principal component analysis (PCA) and (**C**) hierarchical clustering analysis by Partek^®^ GS^®^ confirmed clustering of the datasets from mice belonging to the same experimental or control group.](ijms-21-01296-g001){#ijms-21-01296-f001}

![Gene-set enrichment analysis of deregulated genes in SHS-exposed mice. We performed gene ontology analysis on the 153 unique genes identified in SHS-exposed mice, before and after recovery, relative to controls. (**A**) Eighteen genes are specifically implicated in hepatic steatosis. Red and green nodes represent up-regulated and down-regulated genes, respectively. (**B**) The Functional Clustering Analysis tool in DAVID was used to group together redundant annotations. The top ten categories identified by DAVID, with a group enrichment score between 1.26 and 3.88 (*x*-axis), are listed on the *y*-axis. (**C**) The top canonical pathways and hepatotoxic functions were displayed along with the significance values and number of associated molecules and included, among others, liver steatosis, inflammation and necrosis.](ijms-21-01296-g002){#ijms-21-01296-f002}

![Upstream Regulator Analysis of lipid-specific genes in SHS-exposed mice. We used IPA^®^ Upstream Regulator Analysis to identify the upstream regulators that are likely to account for the aberrant expression of the 63 lipid-specific genes in SHS-exposed mice. Using IPA^®^ prediction analysis, we found that 25 out of the 63 lipid-specific genes are likely to be modulated by a complex network of eleven upstream regulators. For brevity, only gene targets regulated by TP53 are shown. Red molecule, up-regulation; green molecule, down-regulation. Solid and dotted lines indicate a direct or indirect relationship, respectively, between the upstream regulator and its target.](ijms-21-01296-g003){#ijms-21-01296-f003}

![Evaluation of fat accumulation and liver injury in SHS-exposed mice. (**A**) Liver sections from SHS-exposed and control mice were stained with Oil Red O to detect neutral lipid accumulation (red droplets) within the hepatocytes. Microphotographs are shown at 400× original magnifications. Quantification of lipid droplets (graphs on the right) was performed on Oil Red O (ORO)-stained slides (*n* = 4--8) at 400X magnification by measuring the area occupied by red pixels in ImageJ software (<https://imagej.nih.gov/ij/>). \* SHS^4m^ vs. Control 1: *p* = 0.000334; ^¶^ SHS^4m+1m\ recovery^ vs. Control 1: *p* = 0.000276; ^§^ SHS^4m+1m\ recovery^ vs. SHS^4m^: *p* = 0.000017; ^‡^ SHS^4m+7m\ recovery^ vs. Control 2: *p* = 0.000114; ^§§^ SHS^4m+7m\ recovery^ vs. SHS^4m^: *p* \< 0.00001; \*\* Control 2 vs. Control 1: *p* = 0.000508. (**B**) Paraffin-embedded liver sections from experimental and control mice were stained with hematoxylin and eosin (H&E) to examine cell morphology and detect potential manifestations of liver injury. Representative microphotographs are shown at low (scale bar, 200 μM) and high magnifications (scale bar, 50 μM). Top panels (**a**,**d**), control mice; middle panels (**b**,**e**), SHS^4m^ mice; lower panels (**c**,**f**); SHS^4m+1m\ recovery^ mice. Small foci of inflammatory infiltrates and areas of necrosis were observed in the liver of SHS^4m^ and SHS^4m+1m\ recovery^ mice (panels **e**,**f**). SHS^4m+1m\ recovery^ mice exhibited a disrupted cord-like architecture and a great variability in the size and nuclear morphology of hepatocytes (panel **f**). The white arrow shows an area of pronounced liver steatosis. Big black arrows, foci of inflammation; small black arrows, apoptotic cells.](ijms-21-01296-g004){#ijms-21-01296-f004}

![Evaluation of liver fibrosis and glycogen deposition in SHS-exposed mice. Paraffin-embedded liver sections from experimental and control mice were stained with Masson's trichrome (**a**--**f**) and Periodic Acid-Schiff (PAS) stain (**g**--**l**) to evaluate fibrosis and glycogen deposition, respectively. Representative microphotographs are shown at low (scale bar, 200 μM) and high magnifications (scale bar, 50 μM). Panels **a**, **d**, **g**, **j**, control mice; panels **b**, **e**, **h**, **k**, SHS^4m^ mice; panels **c**, **f**, **i**, **l**, SHS^4m+1m\ recovery^ mice. Areas of mild liver fibrosis (blue areas) are increasingly observed in the experimental mice. The white arrow shows an area of pronounced liver steatosis. Black arrows indicated parenchymal invasion of collagen fibers. Prominent loss of glycogen was observed in the liver of SHS^4m^ mice, while SHS^4m+1m\ recovery^ mice and controls show intense and extensive PAS-positive staining.](ijms-21-01296-g005){#ijms-21-01296-f005}

![Gene validation by Reverse Transcription Quantitative PCR (RT-qPCR) and proposed model. (**A**) The expression status of individual gene targets identified by microarray analysis was examined by RT-qPCR. Bars represent the mean normalized gene expression (±SE) in SHS-exposed mice, before recovery (in blue) and after recovery (in red) relative to controls. All reactions (5 samples per experimental and control group) were performed in triplicate for a total of 15 reactions per biological set. Data were normalized using the endogenous housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*), as reference. (**B**) Proposed model of SHS-induced hepatic fat accumulation through the involvement of wild-type p53 and/or gain-of-function p53 mutants. Vertical white arrows indicate up-regulation or down-regulation of target molecules; vertical black arrows show decrease in fatty acid (FA) oxidation or increase in fatty acid (FA) synthesis (see, text).](ijms-21-01296-g006){#ijms-21-01296-f006}
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###### 

List of differentially expressed genes (*n* = 153) identified in the liver of SHS-exposed mice, both before and after recovery time, relative to controls.

  Expression ^1^ Log Ratio   ID              D ^2^   Symbol ^3^                       Entrez Gene Name                                                               Location
  -------------------------- --------------- ------- -------------------------------- ------------------------------------------------------------------------------ ---------------------
  3.543                      1426037_a\_at   D       ***RGS16 \****                   regulator of G-protein signaling 16                                            Cytoplasm
  3.466                      1422557_s\_at   D       ***Mt1***                        metallothionein 1                                                              Cytoplasm
  3.26                       1428942_at              ***Mt2***                        metallothionein 2                                                              Other
  3.245                      1417168_a\_at   D       *USP2*                           ubiquitin specific peptidase 2                                                 Cytoplasm
  2.943                      1422257_s\_at   D       ***CYP2B6***                     cytochrome P450 family 2 subfamily B member 6                                  Cytoplasm
  2.387                      1442025_a\_at   D       ***ZBTB16***                     zinc finger and BTB domain containing 16                                       Nucleus
  2.265                      1418288_at      D       ***LPIN1 \****                   lipin 1                                                                        Nucleus
  2.221                      1427747_a\_at           ***LCN2***                       lipocalin 2                                                                    Extracellular Space
  2.174                      1428223_at              ***MFSD2A \****                  major facilitator superfamily domain containing 2A                             Plasma Membrane
  2.168                      1443147_at      D       ***ACOT1 \****                   acyl-CoA thioesterase 1                                                        Cytoplasm
  2.095                      1416125_at              *FKBP5*                          FK506 binding protein 5                                                        Nucleus
  1.956                      1435188_at              *CIART*                          circadian associated repressor of transcription                                Nucleus
  1.933                      1425837_a\_at           ***NOCT \****                    nocturnin                                                                      Nucleus
  1.922                      1451190_a\_at   D       *SBK1*                           SH3 domain binding kinase 1                                                    Other
  1.87                       1428923_at              ***PPP1R3G***                    protein phosphatase 1 regulatory subunit 3G                                    Cytoplasm
  1.864                      1451548_at      D       *UPP2*                           uridine phosphorylase 2                                                        Cytoplasm
  1.774                      1460241_a\_at   D       ***ST3GAL5***                    ST3 beta-galactoside alpha-2,3-sialyltransferase 5                             Cytoplasm
  1.759                      1419590_at              *Cyp2b13/Cyp2b9*                 cytochrome P450, family 2, subfamily b, polypeptide 9                          Cytoplasm
  1.707                      1416432_at              ***PFKFB3***                     6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3                          Cytoplasm
  1.61                       1429144_at      D       *GPCPD1*                         glycerophosphocholine phosphodiesterase 1                                      Cytoplasm
  1.598                      1434437_x\_at   D       *RRM2*                           ribonucleotide reductase regulatory subunit M2                                 Nucleus
  1.594                      1416933_at              ***POR \****                     cytochrome p450 oxidoreductase                                                 Cytoplasm
  1.542                      1439489_at              ***FFAR4 \****                   free fatty acid receptor 4                                                     Plasma Membrane
  1.542                      1448162_at              ***VCAM1***                      vascular cell adhesion molecule 1                                              Plasma Membrane
  1.523                      1429206_at              *RHOBTB1*                        Rho related BTB domain containing 1                                            Other
  1.518                      1453023_at              *ANKHD1/ANKHD1-EIF4EBP3*         ankyrin repeat and KH domain containing 1                                      Other
  1.493                      1434473_at              *SLC16A5*                        solute carrier family 16 member 5                                              Plasma Membrane
  1.492                      1417761_at      D       ***APOA4***                      apolipoprotein A4                                                              Extracellular Space
  1.469                      1417602_at              ***PER2***                       period circadian clock 2                                                       Nucleus
  1.45                       1425824_a\_at           *PCSK4*                          proprotein convertase subtilisin/kexin type 4                                  Extracellular Space
  1.437                      1448239_at              ***HMOX1 \****                   heme oxygenase 1                                                               Cytoplasm
  1.433                      1452416_at              *IL6R*                           interleukin 6 receptor                                                         Plasma Membrane
  1.418                      1427473_at              *Gstm3*                          glutathione S-transferase, mu 3                                                Cytoplasm
  1.403                      1449851_at              ***PER1***                       period circadian clock 1                                                       Nucleus
  1.38                       1417904_at              *DCLRE1A*                        DNA cross-link repair 1A                                                       Nucleus
  1.336                      1450505_a\_at   D       *FAM134B*                        family with sequence similarity 134, member B                                  Cytoplasm
  1.334                      1440840_at              *SLC16A7*                        solute carrier family 16 member 7                                              Plasma Membrane
  1.302                      1423233_at              ***CEBPD***                      CCAAT/enhancer binding protein delta                                           Nucleus
  1.296                      1416773_at              *WEE1*                           WEE1 G2 checkpoint kinase                                                      Nucleus
  1.279                      1435459_at      D       *FMO2*                           flavin containing monooxygenase 2                                              Cytoplasm
  1.279                      1426452_a\_at           *RAB30*                          RAB30, member RAS oncogene family                                              Cytoplasm
  1.268                      1421681_at      D       *NRG4*                           neuregulin 4                                                                   Extracellular Space
  1.259                      1435495_at              ***ADORA1 \****                  adenosine A1 receptor                                                          Plasma Membrane
  1.251                      1426850_a\_at           ***MAP2K6***                     mitogen-activated protein kinase kinase 6                                      Cytoplasm
  1.247                      1421852_at              *KCNK5*                          potassium two pore domain channel subfamily K member 5                         Plasma Membrane
  1.246                      1443870_at              ***ABCC4***                      ATP binding cassette subfamily C member 4                                      Plasma Membrane
  1.242                      1422230_s\_at           ***CYP2A6 (includes others)***   cytochrome P450 family 2 subfamily A member 6                                  Cytoplasm
  1.239                      1458442_at              *AI132709*                       expressed sequence AI132709                                                    Other
  1.238                      1424175_at              ***TEF***                        TEF, PAR bZIP transcription factor                                             Nucleus
  1.231                      1424744_at              *SDS*                            serine dehydratase                                                             Cytoplasm
  1.213                      1434292_at              *Snhg11*                         small nucleolar RNA host gene 11                                               Other
  1.212                      1418780_at              ***CYP39A1***                    cytochrome P450 family 39 subfamily A member 1                                 Cytoplasm
  1.207                      1453410_at              ***ANGPTL4***                    angiopoietin like 4                                                            Extracellular Space
  1.199                      1456156_at              ***LEPR***                       leptin receptor                                                                Plasma Membrane
  1.198                      1449565_at              ***Cyp2g1***                     cytochrome P450, family 2, subfamily g, polypeptide 1                          Cytoplasm
  1.198                      1449498_at              *MARCO*                          macrophage receptor with collagenous structure                                 Plasma Membrane
  1.197                      1428352_at              *ARRDC2*                         arrestin domain containing 2                                                   Other
  1.185                      1418595_at              *PLIN4*                          perilipin 4                                                                    Cytoplasm
  1.178                      1417042_at              ***SLC37A4***                    solute carrier family 37 member 4                                              Cytoplasm
  1.169                      1426980_s\_at           *EPOP*                           elongin BC and polycomb repressive complex 2 associated protein                Other
  1.164                      1445574_at      D       ***PPARGC1B \****                PPARG coactivator 1 beta                                                       Nucleus
  1.162                      1429809_at              *TMTC2*                          transmembrane and tetratricopeptide repeat containing 2                        Cytoplasm
  1.152                      1455958_s\_at           *PPTC7*                          PTC7 protein phosphatase homolog                                               Cytoplasm
  1.151                      1431339_a\_at   D       *EFHD2*                          EF-hand domain family member D2                                                Other
  1.142                      1428512_at              *BHLHB9*                         basic helix-loop-helix domain containing, class B, 9                           Cytoplasm
  1.141                      1455002_at      D       *PTP4A1*                         protein tyrosine phosphatase type IVA, member 1                                Cytoplasm
  1.133                      1428926_at      D       *FBXO31*                         F-box protein 31                                                               Extracellular Space
  1.123                      1416286_at              ***RGS4***                       regulator of G-protein signaling 4                                             Cytoplasm
  1.115                      1432543_a\_at           *KLF13*                          Kruppel like factor 13                                                         Nucleus
  1.111                      1434456_at              *RUNDC3B*                        RUN domain containing 3B                                                       Other
  1.108                      1435860_at              *SLC5A6*                         solute carrier family 5 member 6                                               Plasma Membrane
  1.102                      1427912_at              *CBR3*                           carbonyl reductase 3                                                           Cytoplasm
  1.098                      1456395_at      D       ***PPARGC1A \****                PPARG coactivator 1 alpha                                                      Nucleus
  1.091                      1454799_at              ***GPAT3***                      glycerol-3-phosphate acyltransferase 3                                         Cytoplasm
  1.047                      1419758_at              ***ABCB1***                      ATP binding cassette subfamily B member 1                                      Plasma Membrane
  1.04                       1423627_at              ***NQO1***                       NAD(P)H quinone dehydrogenase 1                                                Cytoplasm
  1.036                      1438211_s\_at           ***DBP***                        D-box binding PAR bZIP transcription factor                                    Nucleus
  1.032                      1424815_at              *GYS2*                           glycogen synthase 2                                                            Cytoplasm
  1.021                      1448568_a\_at           *SLC20A1*                        solute carrier family 20 member 1                                              Plasma Membrane
  1.007                      1428487_s\_at   D       *COQ10B*                         coenzyme Q10B                                                                  Cytoplasm
  1.007                      1420772_a\_at           ***TSC22D3 \****                 TSC22 domain family member 3                                                   Nucleus
  1.006                      1433816_at              *SLC25A51*                       solute carrier family 25 member 51                                             Cytoplasm
  −1.003                     1439377_x\_at           *CDC20*                          cell division cycle 20                                                         Nucleus
  −1.006                     1455293_at              *LEO1*                           LEO1 homolog, Paf1/RNA polymerase II complex component                         Nucleus
  −1.008                     1431056_a\_at           ***LPL \****                     lipoprotein lipase                                                             Cytoplasm
  −1.013                     1450010_at              ***HSD17B12***                   hydroxysteroid 17-beta dehydrogenase 12                                        Cytoplasm
  −1.022                     1417292_at              *Ifi47*                          interferon gamma inducible protein 47                                          Cytoplasm
  −1.022                     1417792_at              *ZNF638*                         zinc finger protein 638                                                        Nucleus
  −1.027                     1452445_at              *SLC41A2*                        solute carrier family 41 member 2                                              Plasma Membrane
  −1.036                     1448986_x\_at           *DNASE2*                         deoxyribonuclease 2, lysosomal                                                 Cytoplasm
  −1.037                     1436931_at              *RFX4*                           regulatory factor X4                                                           Nucleus
  −1.039                     1450035_a\_at   D       *PRPF40A*                        pre-mRNA processing factor 40 homolog A                                        Nucleus
  −1.04                      1428022_at              ***OBP2B \****                   odorant binding protein 2B                                                     Extracellular Space
  −1.042                     1427356_at              *FAM89A*                         family with sequence similarity 89 member A                                    Other
  −1.042                     1424033_at              *SRSF7*                          serine and arginine rich splicing factor 7                                     Nucleus
  −1.043                     1457758_at              *ENY2*                           ENY2, transcription and export complex 2 subunit                               Nucleus
  −1.045                     1416403_at              ***ABCB10***                     ATP binding cassette subfamily B member 10                                     Cytoplasm
  −1.047                     1450846_at              *BZW1*                           basic leucine zipper and W2 domains 1                                          Cytoplasm
  −1.048                     1438713_at              *RASSF8*                         Ras association domain family member 8                                         Extracellular Space
  −1.051                     1433515_s\_at   D       ***ETNK1***                      ethanolamine kinase 1                                                          Cytoplasm
  −1.057                     1437864_at              ***ADIPOR2 \****                 adiponectin receptor 2                                                         Plasma Membrane
  −1.057                     1451122_at      D       ***IDI1***                       isopentenyl-diphosphate delta isomerase 1                                      Cytoplasm
  −1.061                     1425206_a\_at           *UBE3A*                          ubiquitin protein ligase E3A                                                   Nucleus
  −1.073                     1420379_at              ***Slco1a1***                    solute carrier organic anion transporter family, member 1a1                    Plasma Membrane
  −1.077                     1448183_a\_at           ***HIF1A***                      hypoxia inducible factor 1 alpha subunit                                       Nucleus
  −1.085                     1452030_a\_at           *HNRNPR*                         heterogeneous nuclear ribonucleoprotein R                                      Nucleus
  −1.085                     1428372_at              *ST5*                            suppression of tumorigenicity 5                                                Cytoplasm
  −1.086                     1450484_a\_at           *CMPK2*                          cytidine/uridine monophosphate kinase 2                                        Cytoplasm
  −1.091                     1431024_a\_at           *ARID4B*                         AT-rich interaction domain 4B                                                  Nucleus
  −1.108                     1417832_at              *SMC1A*                          structural maintenance of chromosomes 1A                                       Nucleus
  −1.109                     1424842_a\_at           *ARHGAP24*                       Rho GTPase activating protein 24                                               Cytoplasm
  −1.11                      1455324_at      D       *PLCXD2*                         phosphatidylinositol specific phospholipase C X domain containing 2            Other
  −1.12                      1426458_at              *SLMAP*                          sarcolemma associated protein                                                  Plasma Membrane
  −1.128                     1438269_at              *ZBTB38*                         zinc finger and BTB domain containing 38                                       Nucleus
  −1.131                     1449931_at              *CPEB4*                          cytoplasmic polyadenylation element binding protein 4                          Plasma Membrane
  −1.136                     1442537_at              *CYP2U1*                         cytochrome P450 family 2 subfamily U member 1                                  Cytoplasm
  −1.158                     1449854_at              ***NR0B2***                      nuclear receptor subfamily 0 group B member 2                                  Nucleus
  −1.16                      1427574_s\_at           *SH3D19*                         SH3 domain containing 19                                                       Plasma Membrane
  −1.165                     1435775_at              ***CLOCK***                      clock circadian regulator                                                      Nucleus
  −1.169                     1429772_at      D       *PLXNA2*                         plexin A2                                                                      Plasma Membrane
  −1.171                     1437932_a\_at           *CLDN1*                          claudin 1                                                                      Plasma Membrane
  −1.172                     1423325_at              *PNN*                            pinin, desmosome associated protein                                            Plasma Membrane
  −1.18                      1447927_at      D       *GBP6*                           guanylate binding protein family member 6                                      Cytoplasm
  −1.205                     1425099_a\_at           ***ARNTL \****                   aryl hydrocarbon receptor nuclear translocator like                            Nucleus
  −1.208                     1444512_at              *ARHGAP29*                       Rho GTPase activating protein 29                                               Cytoplasm
  −1.238                     1442367_at              ***ATP11C***                     ATPase phospholipid transporting 11C                                           Plasma Membrane
  −1.27                      1417982_at              ***INSIG2 \****                  insulin induced gene 2                                                         Cytoplasm
  −1.275                     1427513_at              *BC024137*                       cDNA sequence BC024137                                                         Other
  −1.276                     1430896_s\_at           ***NUDT7***                      nudix hydrolase 7                                                              Cytoplasm
  −1.289                     1450090_at              *Zfp101*                         zinc finger protein 101                                                        Nucleus
  −1.295                     1449514_at              ***GRK5***                       G protein-coupled receptor kinase 5                                            Plasma Membrane
  −1.325                     1421092_at              ***SERPINA12***                  serpin family A member 12                                                      Cytoplasm
  −1.343                     1423571_at              ***S1PR1***                      sphingosine-1-phosphate receptor 1                                             Plasma Membrane
  −1.346                     1420531_at              ***Hsd3b4 (includes others)***   hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 4   Cytoplasm
  −1.354                     1422769_at      D       *SYNCRIP*                        synaptotagmin binding cytoplasmic RNA interacting protein                      Nucleus
  −1.379                     1437581_at              *ZNF800*                         zinc finger protein 800                                                        Other
  −1.395                     1430785_at      D       *SDR9C7*                         short chain dehydrogenase/reductase family 9C member 7                         Other
  −1.402                     1426215_at              *DDC \**                         dopa decarboxylase                                                             Cytoplasm
  −1.405                     1426645_at              *HSP90AA1*                       heat shock protein 90 alpha family class A member 1                            Cytoplasm
  −1.434                     1433446_at      D       *HMGCS1*                         3-hydroxy-3-methylglutaryl-CoA synthase 1                                      Cytoplasm
  −1.472                     1423397_at              *UGT2B28*                        UDP glucuronosyltransferase family 2, member B28                               Cytoplasm
  −1.482                     1424709_at      D       ***SC5D***                       sterol-C5-desaturase                                                           Cytoplasm
  −1.509                     1450264_a\_at           ***CHKA***                       choline kinase alpha                                                           Cytoplasm
  −1.554                     1438751_at              *SLC30A10*                       solute carrier family 30 member 10                                             Other
  −1.573                     1417065_at              ***EGR1***                       early growth response 1                                                        Nucleus
  −1.58                      1433944_at              *HECTD2*                         HECT domain E3 ubiquitin protein ligase 2                                      Cytoplasm
  −1.622                     1431817_at              *Adh6-ps1*                       alcohol dehydrogenase 6 (class V), pseudogene 1                                Other
  −1.663                     1439300_at      D       *CHIC1*                          cysteine rich hydrophobic domain 1                                             Plasma Membrane
  −1.666                     1427347_s\_at   D       *TUBB2A*                         tubulin beta 2A class IIa                                                      Cytoplasm
  −1.692                     1450018_s\_at   D       *SLC25A30*                       solute carrier family 25 member 30                                             Cytoplasm
  −1.896                     1448092_x\_at   D       *Serpina4-ps1*                   serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1      Other
  −2.034                     1420722_at              ***ELOVL3***                     ELOVL fatty acid elongase 3                                                    Cytoplasm
  −2.382                     1421447_at      D       ***ONECUT1***                    one cut homeobox 1                                                             Nucleus

^1^ A "positive" (+) fold ratio indicates up-regulation while a "negative" (−) fold ratio indicates down-regulation; ^2^ D, duplicate transcripts were identified for that gene; ^3^ genes involved in lipid metabolism (*n* = 63) are indicated in bold. The asterisk (\*) marks genes known to play a role in liver steatosis.

[^1]: Current address: HANDOK, 132, Teheran-ro, Gangnam-gu, Seoul 06235, Korea.
